medqumica

What medqumica does

MedQuímica Indústria Farmacêutica is a Brazil-based pharmaceutical manufacturer founded in 1977 and headquartered in the Industrial District of Juiz de Fora, Minas Gerais. The company develops, produces, commercializes, and distributes an extensive line of solid and liquid medications organized into five product categories: MIP (Medicamentos Isentos de Prescrição, i.e., over-the-counter medicines), Genéricos de Marca (branded generics), Hospitalar (hospital-channel products), Genéricos (generic medicines), and Suplemento Alimentar (dietary supplements). A featured product, Cuprimine, is marketed for the treatment of Wilson's disease, indicating selective participation in the rare-disease therapeutics segment.

The company holds the ANVISA-issued Certificado de Boas Práticas de Fabricação (CBPF), confirming compliance with Brazilian Good Manufacturing Practices, and has operated continuously in Brazil for 49 years. Since 2015, MedQuímica has been a wholly-owned subsidiary of Grupo Lupin (Lupin Limited, NYSE: LUPIN), an India-headquartered global pharmaceutical group ranked as the 5th largest generic company in the United States by prescriptions and the 8th largest globally. This affiliation gives MedQuímica access to Lupin's international R&D, manufacturing, and quality systems.

MedQuímica operates a sales-led, distribution-driven commercial model, with products reaching pharmacies, hospitals, and healthcare providers across Brazil through traditional pharmaceutical wholesalers and distributors. Revenue is generated through one-time product sales across the OTC, generic, branded generic, hospital, and dietary-supplement categories. No direct-to-consumer digital channel, SaaS layer, or pricing transparency is disclosed, consistent with a traditional B2B/B2B2C pharmaceutical distribution business.

Name

medqumica

Legal name

MedQuímica Indústria Farmacêutica

Website

https://medquimica.com

Company type

Private

Founded year

1977

Operating status

Operating

Short description

MedQuímica is a Brazil-based pharmaceutical manufacturer (founded 1977, Juiz de Fora) developing and distributing solid and liquid medications and dietary supplements across five product lines (OTC, branded generics, hospital products, generics, supplements) to pharmacies, hospitals, and healthcare providers nationwide.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• OTC medications
• Hospital pharmaceuticals
• Dietary supplements
• Branded generics

Headquarters

HQ city

Juiz De Fora

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Products Sales: MedQuímica generates revenue through the development, production, and commercialization of pharmaceutical products including solid and liquid medications across five product lines: MIP (over-the-counter medicines), Genéricos de Marca (brand generics), Hospitalar (hospital products), Genéricos (generic medicines), and Suplemento Alimentar (food supplements). Revenue is derived from product sales to pharmacies, healthcare providers, and hospitals across Brazil.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

MedQuímica develops, manufactures, and distributes pharmaceutical products in solid and liquid dosage forms, plus dietary supplements, sold under five product lines: MIP (over-the-counter medications), Genéricos de Marca (branded generics), Hospitalar (hospital channel), Genéricos (generic medicines), and Suplemento Alimentar (food supplements). The portfolio serves Brazilian pharmacies, hospitals, and healthcare providers through its own distribution infrastructure.

Product overview

MedQuímica is a pharmaceutical company that develops, produces, commercializes, and distributes medications and dietary supplements. The company operates as part of the Lupin Group and offers an extensive line of solid and liquid medications classified into five product lines: MIP (Medicamentos Isentos de Prescrição/OTC medications), Genéricos de Marca (branded generics), Hospitalar (hospital products), Genéricos (generic drugs), and Suplemento Alimentar (dietary supplements). Featured products include Cuprimine for Wilson's disease treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• MIP (Medicamentos Isentos de Prescrição)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Grupo LupincoreStrategic or Co-development Partner · 1 January 2015In 2015, MedQuímica became part of Grupo Lupin, a global pharmaceutical company. Lupin is the 5th largest generic company in the United States by prescriptions and 8th largest generic company worldwide. The partnership provides MedQuímica with access to global pharmaceutical expertise, research capabilities, and quality standards while expanding Lupin's presence in the Brazilian market.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• EMS Pharma: Brazil's largest pharmaceutical company by prescriptions, with broad generics, branded, and OTC portfolios distributed through pharmacy and hospital channels — the most direct domestic competitor to MedQuímica's five-line model.
• Eurofarma Laboratórios: Major Brazilian pharma with diversified generics, branded, OTC, and hospital lines and a strong distribution network across Brazil, directly comparable to MedQuímica's product breadth and GTM model.
• Aché Laboratórios: Brazilian pharma with branded generics, OTC, hospital, and supplement offerings — overlapping directly with MedQuímica's MIP, Genéricos de Marca, Hospitalar, and Suplemento Alimentar lines.
• Hypera Pharma: Largest Brazilian pharma by market cap, with extensive generics, OTC, and consumer health brands; competes head-to-head with MedQuímica across multiple product lines and channels.
• Biolab Farmacêutica: Brazilian pharma focused on prescription generics and specialty prescription products in Brazil, with hospital and retail distribution — comparable in therapeutic categories and channel coverage to MedQuímica.
• Laboratório Cristália: Brazilian pharmaceutical manufacturer with strong presence in hospital injectables, anesthetics, and generics — directly overlapping with MedQuímica's Hospitalar product line and broader generics portfolio.

Broad incumbents

• Sanofi (Brazil): Global pharmaceutical company with a substantial Brazilian operation across OTC, generics, and specialty; competes with MedQuímica in OTC/MIP and branded generics as part of a much broader global portfolio.
• Bayer (Brazil): Multinational pharma with OTC consumer health, prescription, and consumer supplements in Brazil — directly overlapping with MedQuímica's MIP and Suplemento Alimentar lines but operating at much greater scale.

Regional players

• Grupo NC (formerly Lupin Brazil): Brazilian pharma with generics and specialty focus; operates within the broader Latin American generics landscape and serves a comparable customer base to MedQuímica across hospital and retail.
• Torrent Pharmaceuticals (Brazil): Indian generic manufacturer with emerging Brazilian presence, comparable to Lupin/MedQuímica as another India-rooted player expanding into the Brazilian generics and hospital markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about medqumica